Idioma:

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Neelapu, Sattva S. ; Jacobson, Caron A. ; Oluwole, Olalekan O. ; Munoz, Javier ; Deol, Abhinav ; Miklos, David B. ; Bartlett, Nancy L. ; Braunschweig, Ira ; Jiang, Yizhou ; Kim, Jenny J. ; Zheng, Lianqing ; Rossi, John M. ; Locke, Frederick L.

Blood, 2020-06, Vol.135 (23), p.2106-2109 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Autor: Neelapu, Sattva S. ; Jacobson, Caron A. ; Oluwole, Olalekan O. ; Munoz, Javier ; Deol, Abhinav ; Miklos, David B. ; Bartlett, Nancy L. ; Braunschweig, Ira ; Jiang, Yizhou ; Kim, Jenny J. ; Zheng, Lianqing ; Rossi, John M. ; Locke, Frederick L.
Assuntos: Adult ; Aged ; Antigens, CD19 - therapeutic use ; Female ; Follow-Up Studies ; Humans ; Immunotherapy, Adoptive ; Letter to ; Lymphoma, Large B-Cell, Diffuse - immunology ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphoma, Large B-Cell, Diffuse - therapy ; Male ; Middle Aged ; Neoplasm Recurrence, Local - immunology ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - therapy ; Prognosis ; Survival Rate ; Young Adult
É parte de: Blood, 2020-06, Vol.135 (23), p.2106-2109
Notas: SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Feature-1
ObjectType-Correspondence-3
Descrição: Neelapu and colleagues report a post hoc subgroup analysis from the ZUMA-1 trial of chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B cell lymphoma. In comparison with younger patients, those ≥65 years old have similar rates of complete response and durable response at 2 years, but higher rates of neurological toxicity.
Editor: United States: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados